Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

662

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated based on new efficacy data from another study.

Conditions

Depressive Disorder, Major

Interventions

DRUG: Vortioxetine

Sponsor

H. Lundbeck A/S